Follow-up of national procurement violations: hospital returns and replacement companies sign new contracts!

Violations of national procurement must be severely punished! On January 29, 2022, two days before the Spring Festival, Guizhou Shengjitang Pharmaceutical, a company selected for the second batch of Guocai glimepiride tablets, did not meet the quality management of drug production because the company violated the commitments made in the application materials.
Specifications, was issued by the National Federation, disqualified from being selected, and included in the list of violations
.
Prior to this, on January 28, 2022, the Guizhou Provincial Drug Administration issued public information to suspend the production and sales of glimepiride tablets in accordance with the law, and further investigate and deal with it
.
According to the relevant announcement of the Guizhou Food and Drug Administration, from December 23 to December 25, 2021, the Guizhou Provincial Food and Drug Administration conducted an unannounced inspection of Guizhou Shengjitang Pharmaceutical, and the inspection object was glimepiride tablets.
The company has serious defects in plant maintenance, equipment cleaning, stability inspection, etc.
, and comprehensive research and judgment determine that the company does not meet the quality management standards for drug production
.
Subsequently, the joint procurement agency initiated the replacement procedure for glimepiride tablets according to regulations, and other qualified companies selected to supply Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
to the original supply province to ensure the supply of drugs in relevant areas
.
On January 29, 2022, the Joint Procurement Office issued the "Notice on Determining Substitute Suppliers for the Second Batch of Nationally Organized Drug Collection Glimepiride Tablets in Some Areas".
The relevant provisions of the Centralized Drug Procurement Document (GY-YD2019-2), jointly entrusted by the 7 provinces of Shanxi, Shanghai, Jiangsu, Fujian, Guangdong, Guangxi, and Hainan, communicated with relevant parties, and passed relevant procedures such as notarization.
The other 4 companies selected for limepiride tablets, Sichuan Haihui Pharmaceutical Co.
, Ltd.
, Chongqing Kangkeer Pharmaceutical Co.
, Ltd.
, Shandong Xinhua Pharmaceutical Co.
, Ltd.
, and Beijing Beilu Pharmaceutical Co.
, Ltd.
, selected alternate supply areas according to procedures, among which Sichuan Haihui Pharmaceutical supplies Guangdong and Hainan, Chongqing Kangkeer Pharmaceutical supplies Shanghai and Guangxi, Shandong Xinhua Pharmaceutical supplies Jiangsu and Shanxi, and Beijing Beilu Pharmaceutical supplies Fujian
.
Hainan issued alternate work arrangements On February 18, the Hainan Provincial Public Resource Trading Service Center issued the "Notice on Determining the Second Batch of Nationally Organized Drug Collection Varieties Glimepiride Tablets for Substitute Supply Enterprises in Hainan Province".
The notice to determine the replacement enterprise and the requirements of the Hainan Provincial Medical Insurance Bureau, make work arrangements for the replacement supplier of the second batch of nationally organized drug collections of glimepiride tablets in Hainan Province
.
According to the "Notice", the Hainan Provincial Public Resource Trading Service Center has suspended the listing of Glimepiride tablets of Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
on the Hainan platform, and identified Sichuan Haihui Pharmaceutical Co.
, Ltd.
as the second batch of nationally organized drugs The substitute supplier of Glimepiride Tablets in Hainan Province, and has sold its product Glimepiride Tablets (2mg×60 tablets/box, the selected price is 4.
64 yuan/box) (entrusted by Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co.
, Ltd.
) hangs on the Hainan platform
.
The "Notice" stated that each medical institution will sign a contract with a new replacement company, and the specific arrangements are as follows: For the purchased glimepiride tablets of Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, if each medical institution needs to return it, it must be returned before the end of this month.
Complete the return operation on the trading platform
.
From March 1, 2022, the Hainan Provincial Public Resource Transaction Service Center will determine the new contract volume of each medical institution based on the platform statistics, and each medical institution will sign a separate contract with the replacement enterprise Sichuan Haihui Pharmaceutical Co.
,
Ltd.
The amount of tasks to purchase Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
in the early stage is included in the completed agreement purchases
.
Before the signing of the agreement, the medical institution may purchase and sign the agreement in order to ensure the supply of the selected drugs
.
Manufacturers are requested to complete the selection and distribution procedures as soon as possible
.
Other provinces have not yet seen public work arrangements, but according to the previous joint procurement notice, it should also be in progress
.